Inflammation and Cancer: In Medio Stat Nano

Author(s): Roberto Molinaro, Claudia Corbo, Megan Livingston, Michael Evangelopoulos, Alessandro Parodi, Christian Boada, Marco Agostini, Ennio Tasciotti*

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 34 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Cancer treatment still remains a challenge due to the several limitations of currently used chemotherapeutics, such as their poor pharmacokinetics, unfavorable chemical properties, as well as inability to discriminate between healthy and diseased tissue. Nanotechnology offered potent tools to overcome these limitations. Drug encapsulation within a delivery system permitted i) to protect the payload from enzymatic degradation/ inactivation in the blood stream, ii) to improve the physicochemical properties of poorly water-soluble drugs, like paclitaxel, and iii) to selectively deliver chemotherapeutics to the cancer lesions, thus reducing the off-target toxicity, and promoting the intracellular internalization. To accomplish this purpose, several strategies have been developed, based on biological and physical changes happening locally and systemically as a consequence of tumorigenesis. Here, we will discuss the role of inflammation in the different steps of tumor development and the strategies based on the use of nanoparticles that exploit the inflammatory pathways in order to selectively target the tumor-associated microenvironment for therapeutic and diagnostic purposes.

Keywords: Nanomedicine, biomimetic nanoparticles, inflammation, active targeting, cancer, theranostic, inflamed vasculature.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 20 September, 2017
Page: [4208 - 4223]
Pages: 16
DOI: 10.2174/0929867324666170920160030
Price: $65

Article Metrics

PDF: 43
PRC: 1